Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Correction to "Discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3".

Huang C, Liew SS, Lin GR, Poulsen A, Ang MJY, Chia BCS, Chew SY, Kwek ZP, Wee JLK, Ong EH, Retna P, Baburajendran N, Li R, Yu W, Koh-Stenta X, Ngo A, Manesh S, Fulwood J, Ke Z, Chung HH, Sepramaniam S, Chew XH, Dinie N, Lee MA, Chew YS, Low CB, Pendharkar V, Manoharan V, Vuddagiri S, Sangthongpitag K, Joy J, Matter A, Hill J, Keller TH, Foo K.

ACS Med Chem Lett. 2019 Jul 9;10(8):1240. doi: 10.1021/acsmedchemlett.9b00278. eCollection 2019 Aug 8.

2.

Discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3.

Huang C, Liew SS, Lin GR, Poulsen A, Ang MJY, Chia BCS, Chew SY, Kwek ZP, Wee JLK, Ong EH, Retna P, Baburajendran N, Li R, Yu W, Koh-Stenta X, Ngo A, Manesh S, Fulwood J, Ke Z, Chung HH, Sepramaniam S, Chew XH, Dinie N, Lee MA, Chew YS, Low CB, Pendharkar V, Manoharan V, Vuddagiri S, Sangthongpitag K, Joy J, Matter A, Hill J, Keller TH, Foo K.

ACS Med Chem Lett. 2019 May 23;10(6):978-984. doi: 10.1021/acsmedchemlett.9b00170. eCollection 2019 Jun 13. Erratum in: ACS Med Chem Lett. 2019 Jul 09;10(8):1240.

PMID:
31223458
3.

Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.

Ho SY, Wang W, Ng FM, Wong YX, Poh ZY, Tan SWE, Ang SH, Liew SS, Joyner Wong YS, Tan Y, Poulsen A, Pendharkar V, Sangthongpitag K, Manchester J, Basarab G, Hill J, Keller TH, Cherian J.

Eur J Med Chem. 2018 Sep 5;157:610-621. doi: 10.1016/j.ejmech.2018.08.025. Epub 2018 Aug 11.

PMID:
30125722
4.

Fragment-Based Drug Discovery of Potent Protein Kinase C Iota Inhibitors.

Kwiatkowski J, Liu B, Tee DHY, Chen G, Ahmad NHB, Wong YX, Poh ZY, Ang SH, Tan ESW, Ong EH, Nurul Dinie, Poulsen A, Pendharkar V, Sangthongpitag K, Lee MA, Sepramaniam S, Ho SY, Cherian J, Hill J, Keller TH, Hung AW.

J Med Chem. 2018 May 24;61(10):4386-4396. doi: 10.1021/acs.jmedchem.8b00060. Epub 2018 May 4.

PMID:
29688013
5.

Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia.

Yang H, Chennamaneni LR, Ho MWT, Ang SH, Tan ESW, Jeyaraj DA, Yeap YS, Liu B, Ong EH, Joy JK, Wee JLK, Kwek P, Retna P, Dinie N, Nguyen TTH, Tai SJ, Manoharan V, Pendharkar V, Low CB, Chew YS, Vuddagiri S, Sangthongpitag K, Choong ML, Lee MA, Kannan S, Verma CS, Poulsen A, Lim S, Chuah C, Ong TS, Hill J, Matter A, Nacro K.

J Med Chem. 2018 May 24;61(10):4348-4369. doi: 10.1021/acs.jmedchem.7b01714. Epub 2018 May 7.

PMID:
29683667
6.

Scaffold Hopping and Optimization of Maleimide Based Porcupine Inhibitors.

Ho SY, Alam J, Jeyaraj DA, Wang W, Lin GR, Ang SH, Tan ESW, Lee MA, Ke Z, Madan B, Virshup DM, Ding LJ, Manoharan V, Chew YS, Low CB, Pendharkar V, Sangthongpitag K, Hill J, Keller TH, Poulsen A.

J Med Chem. 2017 Aug 10;60(15):6678-6692. doi: 10.1021/acs.jmedchem.7b00662. Epub 2017 Jul 20.

PMID:
28671458
7.

Toward Resolving the Resveratrol Conundrum: Synthesis and in Vivo Pharmacokinetic Evaluation of BCP-Resveratrol.

Goh YL, Cui YT, Pendharkar V, Adsool VA.

ACS Med Chem Lett. 2017 Apr 24;8(5):516-520. doi: 10.1021/acsmedchemlett.7b00018. eCollection 2017 May 11.

8.

Targeting human respiratory syncytial virus transcription anti-termination factor M2-1 to inhibit in vivo viral replication.

Bailly B, Richard CA, Sharma G, Wang L, Johansen L, Cao J, Pendharkar V, Sharma DC, Galloux M, Wang Y, Cui R, Zou G, Guillon P, von Itzstein M, Eléouët JF, Altmeyer R.

Sci Rep. 2016 May 19;6:25806. doi: 10.1038/srep25806.

9.

p53 Maintains Genomic Stability by Preventing Interference between Transcription and Replication.

Yeo CQX, Alexander I, Lin Z, Lim S, Aning OA, Kumar R, Sangthongpitag K, Pendharkar V, Ho VHB, Cheok CF.

Cell Rep. 2016 Apr 5;15(1):132-146. doi: 10.1016/j.celrep.2016.03.011. Epub 2016 Mar 24.

10.

Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells.

Cherian J, Nacro K, Poh ZY, Guo S, Jeyaraj DA, Wong YX, Ho M, Yang HY, Joy JK, Kwek ZP, Liu B, Wee JL, Ong EH, Choong ML, Poulsen A, Lee MA, Pendharkar V, Ding LJ, Manoharan V, Chew YS, Sangthongpitag K, Lim S, Ong ST, Hill J, Keller TH.

J Med Chem. 2016 Apr 14;59(7):3063-78. doi: 10.1021/acs.jmedchem.5b01712. Epub 2016 Apr 5.

PMID:
27011159
11.

Wnt addiction of genetically defined cancers reversed by PORCN inhibition.

Madan B, Ke Z, Harmston N, Ho SY, Frois AO, Alam J, Jeyaraj DA, Pendharkar V, Ghosh K, Virshup IH, Manoharan V, Ong EH, Sangthongpitag K, Hill J, Petretto E, Keller TH, Lee MA, Matter A, Virshup DM.

Oncogene. 2016 Apr 28;35(17):2197-207. doi: 10.1038/onc.2015.280. Epub 2015 Aug 10.

12.

Discovery and Optimization of a Porcupine Inhibitor.

Duraiswamy AJ, Lee MA, Madan B, Ang SH, Tan ES, Cheong WW, Ke Z, Pendharkar V, Ding LJ, Chew YS, Manoharan V, Sangthongpitag K, Alam J, Poulsen A, Ho SY, Virshup DM, Keller TH.

J Med Chem. 2015 Aug 13;58(15):5889-99. doi: 10.1021/acs.jmedchem.5b00507. Epub 2015 Jul 16.

PMID:
26110200
13.

Feedback regulation on PTEN/AKT pathway by the ER stress kinase PERK mediated by interaction with the Vault complex.

Zhang W, Neo SP, Gunaratne J, Poulsen A, Boping L, Ong EH, Sangthongpitag K, Pendharkar V, Hill J, Cohen SM.

Cell Signal. 2015 Mar;27(3):436-42. doi: 10.1016/j.cellsig.2014.12.010. Epub 2014 Dec 19.

14.

Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.

Choong ML, Pecquet C, Pendharkar V, Diaconu CC, Yong JW, Tai SJ, Wang SF, Defour JP, Sangthongpitag K, Villeval JL, Vainchenker W, Constantinescu SN, Lee MA.

J Cell Mol Med. 2013 Nov;17(11):1397-409. doi: 10.1111/jcmm.12156. Epub 2013 Nov 19.

15.

Reduction of influenza virus-induced lung inflammation and mortality in animals treated with a phosophodisestrase-4 inhibitor and a selective serotonin reuptake inhibitor.

Sharma G, Champalal Sharma D, Hwei Fen L, Pathak M, Bethur N, Pendharkar V, Peiris M, Altmeyer R.

Emerg Microbes Infect. 2013 Aug;2(8):e54. doi: 10.1038/emi.2013.52. Epub 2013 Aug 21.

16.

Fragment-based ligand design of novel potent inhibitors of tankyrases.

Larsson EA, Jansson A, Ng FM, Then SW, Panicker R, Liu B, Sangthongpitag K, Pendharkar V, Tai SJ, Hill J, Dan C, Ho SY, Cheong WW, Poulsen A, Blanchard S, Lin GR, Alam J, Keller TH, Nordlund P.

J Med Chem. 2013 Jun 13;56(11):4497-508. doi: 10.1021/jm400211f. Epub 2013 Jun 4.

PMID:
23672613
17.

Identification and characterization of a small-molecule inhibitor of Wnt signaling in glioblastoma cells.

De Robertis A, Valensin S, Rossi M, Tunici P, Verani M, De Rosa A, Giordano C, Varrone M, Nencini A, Pratelli C, Benicchi T, Bakker A, Hill J, Sangthongpitag K, Pendharkar V, Liu B, Ng FM, Then SW, Jing Tai S, Cheong SM, He X, Caricasole A, Salerno M.

Mol Cancer Ther. 2013 Jul;12(7):1180-9. doi: 10.1158/1535-7163.MCT-12-1176-T. Epub 2013 Apr 25.

18.

Pharmacological inhibition of the Wnt acyltransferase PORCN prevents growth of WNT-driven mammary cancer.

Proffitt KD, Madan B, Ke Z, Pendharkar V, Ding L, Lee MA, Hannoush RN, Virshup DM.

Cancer Res. 2013 Jan 15;73(2):502-7. doi: 10.1158/0008-5472.CAN-12-2258. Epub 2012 Nov 27.

Supplemental Content

Loading ...
Support Center